Australia’s 'Unrealistic' Randomized Controlled Trial Proposal Comes Under Fire
Executive Summary
Industry is not entirely happy with the Therapeutic Goods Administration’s proposed guidelines on clinical evidence requirements.
You may also be interested in...
Australia Accepts Three Approval Pathways, Defers Registry For High-Risk Devices
The Australian government plans to introduce a series of regulatory reforms for devices and drugs over a period of three years, including moves to speed up access to innovative devices and to better leverage assessments by overseas regulators. The changes may include some recovery of costs from industry.
Australia’s TGA To Stamp Out Clinical Evidence Mistakes By Industry
The Australian Therapeutic Goods Administration is attempting to clarify its expectations on clinical evidence requirements for medical devices to stop the many errors companies are making in their submissions for market authorization.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.